1585219-04-0

MO-I-500 is a FTO inhibitor (IC50 = 8.7 μM for purified FTO in vitro), which increases N6-methyladenosine (m6A) levels in total cellular mRNA in HeLa cells. MO-I-500 modulates levels of specific miRNAs. In a triple-negative breast cancer cell line metabolically challenged by culture without glutamine (SUM149-MA cells), MO-I-500 inhibits cell proliferation. MO-I-500 also displays anticonvulsant activity in a 6 Hz mouse model of epilepsy at nontoxic doses.

MO-I-500 is a pharmacological of FTO inhibitor with an IC50 of 8.7 μM for the inhibition of purified FTO demethylase catalyzing demethylation of an artificial small methylated substrate. MO-I-500 can be used for the research of rare panresistant triple-negative inflammatory breast cancer[1].

Store at -20°C

[1] Balraj Singh et al. Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge. PLoS One. 2016 Jul 8;11(7):e0159072. DOI:10.1371/journal.pone.0159072